Crosslinked CXCR4 Signals Decreased Motility and Increased Adhesion of T Cells
Jordan A. PearsoniD, Jung‐In YangiD, Sean KrivitskyiD, Z KelleyiD, Douglas T. FearoniD
Abstract
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive cancer known for its ability to evade immune surveillance, primarily through mechanisms that prevent T cell infiltration. While the coating of cancer cells with the chemokine, CXCL12, is required for the exclusion of T cells, the precise molecular mechanisms behind the failure of T cell migration into the tumor remain unclear. In this study, we identify a potential mechanism by demonstrating that crosslinking CXCR4 is associated with decreased motility of T cells secondary to their adhesion to fibronectin. Using human lymphoblastoid T cells and primary human T cells, we show that polymeric CXCL12-induced crosslinked CXCR4 triggers the non-G i-dependent pathway of tyrosine phosphorylation of FAK-related proline-rich tyrosine kinase 2 (PTK2B) in T cells. This response is necessary for the decreased motility and increased adhesion of T cells. We also find that the downstream cellular reactions of this pathway is secondary to CXCR4-crosslinking and require the integrin subunit, 4, and TNF stimulation of TNFRSF1B. These findings provide insights into the mechanisms mediating the exclusion of T cells from nests of PDA cells and further support therapeutic strategies aimed at blocking the interaction of CXCR4 on T cells with the CXCL12-coating of PDA cells.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pancreatic cancer cells assemble a CXCL12-keratin 19 coating to resist immunotherapy
Z. Wang, R. Yan, … D. T. Fearon·bioRxiv·Sep 4, 2020
- Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma
A. G. Raufi, I. Pellicciotta, … G. A. Manji·bioRxiv·Dec 24, 2023
- Dual blockade of IL-6 and CTLA-4 regresses pancreatic tumors in a CD4+ T cell-dependent manner.
M. B. Ware, C. McQuinn, … G. B. Lesinski·bioRxiv·Feb 7, 2020
- Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells
Kanishka Tiwary, Anton Lahusen, … Patrick Christian Hermann·bioRxiv·Mar 3, 2025
- Interleukin 6 drives durable T cell-mediated immunity to pancreatic cancer
Paige C. Arneson‐Wissink, Alexandra Q. Bartlett, … Aaron J. Grossberg·Cellular and Molecular Gastroenterology and HepatologyPeer-reviewed·Jan 1, 2026
- DDR1-INDUCED NEUTROPHIL EXTRACELLULAR TRAPS DRIVE PANCREATIC CANCER METASTASIS
J. Deng, Y. Kang, … J. B. Fleming·bioRxiv·Aug 5, 2020